Quantcast

Latest Roswell Park Cancer Institute Stories

2008-10-07 09:00:14

The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform. The NCCN...

2008-09-30 12:00:48

RALEIGH, N.C., Sept. 30 /PRNewswire/ -- The physicians and staff of Cancer Centers of North Carolina are pleased to announce the arrival of Dr. Monica Brown Jones, gynecological oncologist and surgeon. Dr. Jones is the 17th oncologist to join CCNC, making it the Triangle's largest group of cancer physicians in private practice. Dr. Jones has practiced oncology and gynecologic oncology and surgery at the Mayo Clinic College of Medicine in Rochester, MN. For five years she served as an...

2008-09-29 09:00:58

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conference will be held at the Grand Hyatt New York Hotel. The Maxim Group Growth Conference will feature interactive presentations from over 80 companies, as well as one-on-one meetings with executives from the Healthcare, Technology, Shipping/Transportation and Emerging Growth Sectors. Attendees will...

2008-09-23 09:01:09

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it will present Protectan CBLB502 at the 2008 Biomedical Advanced Research and Development Authority (BARDA) Stakeholders Workshop and Industry Day, September 24-26, in Washington, DC. Cleveland BioLabs Chief Scientific Officer, Andrei Gudkov, Ph.D., D. Sci., has been invited to speak on Wednesday, September 24, at the Radiological and Nuclear Therapeutics Session. His presentation, titled "Protectan CBLB502 Prevents and Mitigates...

2008-09-16 12:00:50

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) has awarded the Company a contract under the Broad Agency Announcement titled, "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation," for selected tasks in the advanced development of Protectan CBLB502. The total contract...

2008-09-12 09:00:51

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has been awarded a $774,183 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic (blood/bone marrow) damage from radiation exposure. The grant program, Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure, is...

2008-09-10 12:00:51

The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Drugs & Biologics Compendium(TM) Non-Small Cell Lung Cancer. The following changes relate to use in the treatment of Non-Small Cell Lung Cancer and are as follows: -- Cetuximab (Erbitux, Bristol-Myers Squibb/ImClone Systems Incorporated) - First-line therapy for recurrence or metastasis in combination with vinorelbine and cisplatin for performance status 0-2 patients at least 18 years of age...

2008-09-02 12:00:33

The Grizzard Communications Group, an industry leader in integrated, direct response marketing and fundraising, today announced the results of a survey investigating the effects of current economic conditions on donors to charitable causes. Survey results indicate that only 13 percent of respondents expect to increase their giving for the remainder of 2008, while nearly a third (29%) admit to decrease their giving. Surprisingly, donors aged 25-34 were more likely to increase their giving in...

2008-08-07 09:01:05

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today the allowance from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in human volunteers with Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed under the FDA's animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident. This approval pathway...

2008-08-07 03:00:35

More than $12.6 million awarded for pediatric oncology research For St. Baldrick's Foundation Jayme Burnett, 919-334-3779 jayme.burnett@fleishman.com Logo: http://www.StBaldricks.org The St. Baldrick's Foundation, a non-profit organization dedicated to raising money for childhood cancer research, announced today the organization's first round of 2008 research grants, pediatric oncology fellowships and career development awards. St. Baldrick's began as a challenge between friends,...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related